Scn9A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | SCN9A |
|---|---|
| Full Name | Sodium Voltage-Gated Channel Alpha Subunit 9 |
| Chromosomal Location | 2q24.1 |
| NCBI Gene ID | 6335 |
| OMIM | 603415 |
| Ensembl ID | ENSG00000169432 |
| UniProt ID | Q15858 |
| Aliases | Nav1.7, NNa, NE-Na |
The SCN9A gene encodes the alpha subunit of the voltage-gated sodium channel Nav1.7, a member of the Nav1 family of sodium channels. Nav1.7 is primarily expressed in peripheral sensory neurons including nociceptors and olfactory sensory neurons, where it plays a critical role in action potential initiation and propagation. Gain-of-function mutations in SCN9A cause painful disorders including inherited erythromelalgia and paroxysmal extreme pain disorder, while loss-of-function mutations cause congenital insensitivity to pain.
Nav1.7 channels are voltage-gated sodium channels that mediate the rapid depolarization phase of action potentials in excitable cells. The alpha subunit forms the ion-conducting pore, while auxiliary beta subunits modulate channel trafficking and kinetics.
| Brain Region | Expression Level | Notes |
|---|---|---|
| Peripheral Nervous System | High | Dorsal root ganglia, trigeminal ganglia |
| Olfactory Epithelium | High | Olfactory sensory neurons |
| Sympathetic Ganglia | Moderate | Postganglionic neurons |
| Spinal Cord | Low-Moderate | Sensory relay neurons |
| Brain | Low | Limited expression |
| Approach | Drug/Agent | Status | Notes |
|---|---|---|---|
| Blocker | ProTx-II | Research | Spider toxin, highly selective Nav1.7 blocker |
| Blocker | PF-05089771 | Clinical Trials | Selective Nav1.7 blocker for pain |
| Blocker | CNV1014802 | Clinical Trials | Sodium channel blocker for trigeminal neuralgia |
| Blocker | XEN402 | Research | Nav1.7 blocker for pain |
The study of Scn9A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.